
Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
                                    Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa | 
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa | 
|---|---|---|---|---|---|---|
- 在被纳入优先审评及临床急需境外新药名单后加速获批 -...
Read more about 安斯泰来富马酸吉瑞替尼片获中国国家药品监督管理局附条件批准用于治疗携带FLT3突变的复发性或难治性急性髓系白血病成人患者
北京,2020年11月23日——安斯泰来宣布,用于治疗携带FLT3突变的复发性或难治性急性髓系白血病(AML)成人患者的XOSPATA®(英文通用名:gilteritinib...
安可坦®目前已获NMPA批准用于治疗非转移性和转移性去势抵抗性前列腺癌...
数据同时在《新英格兰医学杂志》上发表,并在2020 ASCO线上年会中介绍...
Read more about PROSPER最终结果显示安可坦®(恩扎卢胺)可显著延长非转移性去势抵抗性前列腺癌男性的总生存期
东京,2020年4月10日——安斯泰来制药集团(TSE:4503,总裁兼首席执行官:安川健司博士,“安斯泰来”)今天宣布中国国家药品监督管理局(NMPA)
Read more about 安斯泰来宣布中国国家药品监督管理局受理XOSPATA® 吉瑞替尼(gilteritinib)上市申请
